Efficient granulocyte collection method using high concentrations of medium molecular weight hydroxyethyl starch

Granulocyte transfusion therapy is a rational therapeutic option for patients with prolonged, severe neutropenia. Although high molecular weight hydroxyethyl starch (hHES) facilitates the separation of red blood cells during granulocyte collection, renal dysfunction has been noted as a potential side effect. HES130/0.4 (Voluven®) is a medium molecular weight HES (mHES) with superior safety profiles compared to hHES. Although HES130/0.4 is reportedly effective in the collection of granulocytes, we lack studies comparing the efficiency of granulocyte collection using HES130/0.4 and hHES.

[1]  R. Strauss.  Commentary on White blood cell transfusions for control of infections in neutropenic patients by Vallejos C. (Transfusion 1975; 15(1):28–33) , 2022, Transfusion.

[2]  Ranjan Kumar,et al.  A pilot study on impact of use of medium molecular weight hydroxyethyl starch in granulocyte apheresis using Spectra Optia. , 2022, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[3]  Lin Sun,et al.  The comparison of albumin and 6% hydroxyethyl starches (130/0.4) in cardiac surgery: a meta-analysis of randomized controlled clinical trials , 2021, BMC Surgery.

[4]  K. Akashi,et al.  Granulocyte collection by polymorphonuclear cell-targeting apheresis with medium-molecular-weight hydroxyethyl starch , 2021, International Journal of Hematology.

[5]  S. Jaber,et al.  Effect of Hydroxyethyl Starch vs Saline for Volume Replacement Therapy on Death or Postoperative Complications Among High-Risk Patients Undergoing Major Abdominal Surgery: The FLASH Randomized Clinical Trial. , 2020, JAMA.

[6]  H. Hirai,et al.  Successful granulocyte apheresis using medium molecular weight hydroxyethyl starch , 2019, International Journal of Hematology.

[7]  Yonggoo Kim,et al.  Analysis of hematologic parameters of donors, patients, and granulocyte concentrates to predict successful granulocyte transfusion , 2019, Blood research.

[8]  Kimberly L Klein,et al.  Historical Perspectives, Current Status, and Ethical Issues in Granulocyte Transfusion. , 2017, Annals of clinical and laboratory science.

[9]  E. Scott,et al.  Continuous CD34+ cell collection by a new device is safe and more efficient than by a standard collection procedure: results of a two‐center, crossover, randomized trial , 2016, Transfusion.

[10]  G. Murphy,et al.  Meta‐analysis of colloids versus crystalloids in critically ill, trauma and surgical patients , 2016, The British journal of surgery.

[11]  W. G. Nichols,et al.  Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. , 2015, Blood.

[12]  A. Kurz,et al.  The impact of hydroxyethyl starches in cardiac surgery: a meta-analysis , 2014, Critical Care.

[13]  K. Kawa,et al.  Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry , 2013, Bone Marrow Transplantation.

[14]  T. Fujioka,et al.  Impact of the mobilization regimen and the harvesting technique on the granulocyte yield in healthy donors for granulocyte transfusion therapy , 2012, Transfusion.

[15]  B. Guidet,et al.  Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study , 2012, Critical Care.

[16]  P. Navsaria,et al.  Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). , 2011, British journal of anaesthesia.

[17]  E. Freireich.  Leukocyte transfusion and the development of the continuous-flow blood cell separator. , 2011, Transfusion medicine reviews.

[18]  R. Strauss,et al.  Preparation of granulocyte concentrates by apheresis: collection modalities in the USA , 2011, Vox sanguinis.

[19]  P. Sonneveld,et al.  Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch , 2006, Transfusion.

[20]  H. Eichler,et al.  Tolerance of granulocyte donors towards granulocyte colony‐stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study , 2003, Vox sanguinis.

[21]  A. Remaley,et al.  Controlled study of citrate effects and response to IV calcium administration during allogeneic peripheral blood progenitor cell donation , 2002, Transfusion.

[22]  D. Stroncek,et al.  Administration of G–CSF plus dexamethasone producesgreater granulocyte concentrate yields while causing nomore donor toxicity than G–CSF alone , 2001, Transfusion.

[23]  H. Klein,et al.  A controlled comparison of the efficacy of hetastarch and pentastarch in granulocyte collections by centrifugal leukapheresis. , 1995, Blood.

[24]  A. BØyum,et al.  Separation of Leucocytes: Improved Cell Purity by Fine Adjustments of Gradient Medium Density and Osmolality , 1991, Scandinavian journal of immunology.

[25]  J. Mishler,et al.  Serial Infusion Effects of Hydroxyethyl Starch on ESR, Blood Typing and Crossmatching and Serum Amylase Levels 1 , 1977, Vox sanguinis.

[26]  J. Waitzinger,et al.  Hydroxyethyl Starch (HES) [130/0.4], a New HES Specification , 2003, Drugs in R&D.